Brodsky & Smith law firm is investigating Lisata Therapeutics' Board of Directors for possible breaches of fiduciary duty related to the company's sale to Kuva Labs at $4.00 per share plus contingent value rights. The investigation questions whether the board conducted a fair process and if the deal offers fair value to shareholders. Shareholders can contact the firm for legal advice without cost. This probe could impact shareholder confidence and the final outcome of the acquisition deal.
BlackRock Asset Management Canada announced changes to the risk levels of certain iShares ETFs effective June 19, 2026. The iShares India Index ETF and iShares 20+ Year U.S. Treasury Bond Index ETF (in CAD) have their risk levels lowered from medium-...
Bunker Hill Mining Corp. announced the immediate resignation of director Mark Child, who contributed to advancing the restart of the historic Bunker Hill Mine in Idaho. The company thanked Child for his service during a key redevelopment phase and wi...
America’s Car-Mart, Inc. has amended its Credit and Guaranty Agreement with lenders to gain covenant relief and extend the timeline for its ongoing strategic review. This amendment waives certain defaults and provides a runway through September 2026,...
BlackRock Asset Management Canada has revised the investment risk ratings for three iShares ETFs, lowering the risk for the iShares India Index ETF and the Canadian dollar units of the iShares 20+ Year U.S. Treasury Bond Index ETF from Medium to High...
The iShares MSCI Emerging Markets ETF (EEM) charges a 0.69% annual fee, significantly higher than the 0.09% fee of its similar counterpart, the iShares Core MSCI Emerging Markets ETF (IEMG). Both funds offer nearly identical exposure to emerging mark...
